Astria Therapeutics Inc (NAS:ATXS)
$ 9.14 -0.14 (-1.51%) Market Cap: 501.90 Mil Enterprise Value: 235.18 Mil PE Ratio: 0 PB Ratio: 1.84 GF Score: 36/100

Catabasis Pharmaceuticals Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript

Jul 13, 2021 / 04:30PM GMT
Release Date Price: $10.92 (-8.08%)
Michael Higgins
Ladenburg Thalmann & Co. Inc. - Analyst

Welcome to the Ladenburg Thalmann virtual healthcare conference. My name is Michael Higgins, managing director, senior biotech analyst here. Proud to cover Catabasis; ticker CATB. Launched coverage earlier this year. Happy to have their presentation at our conference. This young company became public as Catabasis earlier this year. And the CEO to present, Jill Milne. Jill, I'll have you take it away. Thank you for joining us.

Jill Milne
Catabasis Pharmaceuticals, Inc. - Co-Founder & Chief Executive Officer

Great. Thank you, Michael. Happy to be here. During my presentation today, I will make statements related to our business based on current and future expectations that might be considered forward-looking statements. And with that, I will get started.

Today I am here to share what we at Catabasis see as a really exciting opportunity to develop what could be the most patient-friendly treatment option for hereditary angioedema patients. This opportunity is in a rare disease with well

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot